Published in J Cell Commun Signal on January 21, 2009
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov (2011) 3.26
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair (2011) 1.61
Cutaneous wound healing: recruiting developmental pathways for regeneration. Cell Mol Life Sci (2012) 1.40
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol (2012) 1.33
Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo. J Cell Commun Signal (2009) 1.33
Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal (2009) 1.30
LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J (2013) 1.18
Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2. J Cell Commun Signal (2009) 1.09
Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling. J Biol Chem (2013) 1.07
Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair (2011) 1.05
Alternative splicing of CCN mRNAs .... it has been upon us. J Cell Commun Signal (2009) 1.01
The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS One (2011) 1.01
TGF-β3 modulates the inflammatory environment and reduces scar formation following vocal fold mucosal injury in rats. Dis Model Mech (2013) 0.97
The role of CCN2 in cartilage and bone development. J Cell Commun Signal (2011) 0.96
Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF. Autophagy (2014) 0.95
Connective tissue growth factor regulates retinal neovascularization through p53 protein-dependent transactivation of the matrix metalloproteinase (MMP)-2 gene. J Biol Chem (2012) 0.93
TGF-β-stimulated CTGF production enhanced by collagen and associated with biogenesis of a novel 31-kDa CTGF form in human corneal fibroblasts. Invest Ophthalmol Vis Sci (2010) 0.90
Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators Inflamm (2012) 0.90
Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal (2011) 0.89
FosB regulates stretch-induced expression of extracellular matrix proteins in smooth muscle. Am J Pathol (2011) 0.89
Pericytes display increased CCN2 expression upon culturing. J Cell Commun Signal (2009) 0.88
Mechanisms of bronchopulmonary dysplasia. J Cell Commun Signal (2013) 0.88
Fell-Muir lecture: Connective tissue growth factor (CCN2) -- a pernicious and pleiotropic player in the development of kidney fibrosis. Int J Exp Pathol (2012) 0.87
Paracrine functions of fibrocytes to promote lung fibrosis. Expert Rev Respir Med (2014) 0.86
Dexamethasone Stiffens Trabecular Meshwork, Trabecular Meshwork Cells, and Matrix. Invest Ophthalmol Vis Sci (2015) 0.86
Yin and Yang Part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2. J Cell Commun Signal (2010) 0.85
When there's smoke there's.....CCN2. J Cell Commun Signal (2010) 0.85
Gene delivery of TGF-β1 induces arthrofibrosis and chondrometaplasia of synovium in vivo. Lab Invest (2010) 0.85
Increased serum and musculotendinous fibrogenic proteins following persistent low-grade inflammation in a rat model of long-term upper extremity overuse. PLoS One (2013) 0.85
Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family. J Cell Commun Signal (2012) 0.84
Molecular control of vascular development by the matricellular proteins CCN1 (Cyr61) and CCN2 (CTGF). Trends Dev Biol (2013) 0.83
Transcriptional and post-translational regulation of the quiescence factor and putative tumor suppressor p150(Sal2). FASEB J (2011) 0.83
Inflammatory biomarkers in serum in subjects with and without work related neck/shoulder complaints. BMC Musculoskelet Disord (2014) 0.83
CCN2 is not required for skin development. J Cell Commun Signal (2011) 0.82
Eyeing the Cyr61/CTGF/NOV (CCN) group of genes in development and diseases: highlights of their structural likenesses and functional dissimilarities. Hum Genomics (2015) 0.80
Vitreous TIMP-1 levels associate with neovascularization and TGF-β2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy. J Cell Commun Signal (2012) 0.79
Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization. Adv Drug Deliv Rev (2016) 0.79
Trial by CCN2: a standardized test for fibroproliferative disease? J Cell Commun Signal (2009) 0.78
CCN2: a bona fide target for anti-fibrotic drug intervention. J Cell Commun Signal (2011) 0.78
TGFβ receptor I transactivation mediates stretch-induced Pak1 activation and CTGF upregulation in mesangial cells. J Cell Sci (2013) 0.78
Blockade of CCN4 attenuates CCl4-induced liver fibrosis. Arch Med Sci (2015) 0.77
Elevated Plasma Connective Tissue Growth Factor Levels in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Pediatr Cardiol (2015) 0.76
Elevation of intraocular pressure in rodents using viral vectors targeting the trabecular meshwork. Exp Eye Res (2015) 0.76
Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma. J Cell Commun Signal (2009) 0.76
Tracheal Aspirate Levels of the Matricellular Protein SPARC Predict Development of Bronchopulmonary Dysplasia. PLoS One (2015) 0.76
Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts. Respir Res (2017) 0.75
Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles. J Neuromuscul Dis (2016) 0.75
Directed differentiation of skin-derived precursors into fibroblast-like cells. Int J Clin Exp Pathol (2014) 0.75
Lysophosphatidic acid signaling through its receptor initiates profibrotic epithelial cell fibroblast communication mediated by epithelial cell derived connective tissue growth factor. Kidney Int (2016) 0.75
Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis. Invest Ophthalmol Vis Sci (2017) 0.75
Connective Tissue Growth Factor Promotes Pulmonary Epithelial Cell Senescence and Is Associated with COPD Severity. COPD (2016) 0.75
What's in an intron? CCN1 mRNA splicing in cancer. J Cell Commun Signal (2009) 0.75
Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression. Cytokine Growth Factor Rev (2017) 0.75
Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. Sci Rep (2017) 0.75
All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci (2006) 5.18
Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev (1997) 3.86
Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol (1991) 3.41
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell (1993) 3.17
A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ (1996) 3.05
A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95
Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol (2002) 2.45
Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem (2004) 2.35
Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem (2003) 2.35
Expression of connective tissue growth factor in human renal fibrosis. Kidney Int (1998) 2.19
Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol (2004) 2.19
CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem (2006) 1.96
Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology (1999) 1.94
Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing. J Invest Dermatol (2008) 1.92
CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int (2002) 1.77
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One (2008) 1.68
Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J (2002) 1.64
Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol (2008) 1.56
Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem (2004) 1.52
Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol (2004) 1.52
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol (2007) 1.46
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum (2007) 1.45
Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) (2002) 1.39
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest (2001) 1.39
Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol (2000) 1.38
The induction of CCN2 by TGFbeta1 involves Ets-1. Arthritis Res Ther (2006) 1.33
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum (2006) 1.30
N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM (2005) 1.28
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol (2001) 1.24
Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem (2003) 1.24
Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care (2003) 1.22
The gene expression profile induced by Wnt 3a in NIH 3T3 fibroblasts. J Cell Commun Signal (2008) 1.21
Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care (2006) 1.20
TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol (2005) 1.14
Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant (2006) 1.14
Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK. J Cell Commun Signal (2007) 1.13
Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis. J Pathol (2006) 1.10
Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy. J Diabetes Complications (2008) 1.10
Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem (2006) 1.09
Regulation of connective tissue growth factor expression by prostaglandin E(2). Am J Physiol (1999) 1.09
Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun (1998) 1.08
Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail (2008) 1.07
Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome. Exp Cell Res (2001) 1.05
Hypoxic regulation of stability of connective tissue growth factor/CCN2 mRNA by 3'-untranslated region interacting with a cellular protein in human chondrosarcoma cells. Oncogene (2006) 1.05
Connective tissue growth factor promoter activity in normal and wounded skin. Fibrogenesis Tissue Repair (2008) 1.05
CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol (2007) 1.02
Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int (2003) 0.98
Regulation of CCN2 mRNA expression and promoter activity in activated hepatic stellate cells. J Cell Commun Signal (2008) 0.97
Welcome to fibrogenesis & tissue repair. Fibrogenesis Tissue Repair (2008) 0.90
9-Cis-retinoic acid exhibits antifibrotic activity via the induction of cyclooxygenase-2 expression and prostaglandin E2 production in scleroderma fibroblasts. Clin Exp Dermatol (2008) 0.88
Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol (2001) 0.87
The 5' untranslated regions (UTRs) of CCN1, CCN2, and CCN4 exhibit cryptic promoter activity. J Cell Commun Signal (2007) 0.85
The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1. Nephrology (Carlton) (2007) 0.84
The Starbuck stops here: it's a Smad world. J Cell Commun Signal (2008) 0.79
Ceramide inhibits CCN2 expression in fibroblasts. J Cell Commun Signal (2008) 0.78
In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse. Hum Mol Genet (2006) 3.90
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem (1989) 3.26
A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95
CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell (2004) 1.83
Hydrophobicity: is LogP(o/w) more than the sum of its parts? Eur J Med Chem (2000) 1.68
RPGR-ORF15, which is mutated in retinitis pigmentosa, associates with SMC1, SMC3, and microtubule transport proteins. J Biol Chem (2005) 1.67
Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum (2010) 1.64
CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp Cell Res (2006) 1.57
Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts. Respir Res (2004) 1.55
Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol (2001) 1.55
The enigma of the liganded hemoglobin end state: a novel quaternary structure of human carbonmonoxy hemoglobin. Biochemistry (2005) 1.54
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Two simple methods for quantifying low-affinity dye-substrate binding. J Histochem Cytochem (1989) 1.45
Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum (2002) 1.40
HINT: a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aided Mol Des (1991) 1.37
Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with perivascular retinal pigment epithelium atrophy. Am J Hum Genet (2007) 1.33
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res (2000) 1.30
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol (2001) 1.24
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum (1999) 1.15
Retinitis Pigmentosa GTPase Regulator (RPGR) protein isoforms in mammalian retina: insights into X-linked Retinitis Pigmentosa and associated ciliopathies. Vision Res (2007) 1.08
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J (2009) 1.08
Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum (2012) 1.06
Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors. J Med Chem (1991) 1.06
X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with FMN at 1.8 A resolution. Structure (2000) 1.00
Swainsonine affects the processing of glycoproteins in vivo. FEBS Lett (1983) 1.00
Requirement of transforming growth factor beta-activated kinase 1 for transforming growth factor beta-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts. Arthritis Rheum (2009) 0.99
Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol (1998) 0.97
Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) (2005) 0.97
Endothelin-1 stimulates colon cancer adjacent fibroblasts. Int J Cancer (2011) 0.96
The X-ray structure determination of bovine carbonmonoxy hemoglobin at 2.1 A resoultion and its relationship to the quaternary structures of other hemoglobin crystal froms. Protein Sci (2001) 0.95
Physiological and x-ray studies of potential antisickling agents. Proc Natl Acad Sci U S A (1983) 0.95
Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol (1998) 0.95
Fibroblast adhesion results in the induction of a matrix remodeling gene expression program. Matrix Biol (2008) 0.93
Effect of vein graft harvesting on endothelial nitric oxide synthase and nitric oxide production. Ann Thorac Surg (2005) 0.93
High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Sci (2001) 0.93
Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae). J Pharm Sci (1972) 0.93
Structure of human erythrocyte catalase. Acta Crystallogr D Biol Crystallogr (2000) 0.92
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum (1997) 0.92
Fibrosis caused by loss of PTEN expression in mouse fibroblasts is crucially dependent on CCN2. Arthritis Rheum (2013) 0.91
Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res (2013) 0.91
Effect of nitric oxide and peroxynitrite on type I collagen synthesis in normal and scleroderma dermal fibroblasts. Free Radic Biol Med (2007) 0.91
Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford) (2010) 0.90
Toll-like receptors in ischaemia and its potential role in the pathophysiology of muscle damage in critical limb ischaemia. Cardiol Res Pract (2012) 0.89
Computational methodology for estimating changes in free energies of biomolecular association upon mutation. The importance of bound water in dimer-tetramer assembly for beta 37 mutant hemoglobins. Biochemistry (2000) 0.89
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents. J Med Chem (1991) 0.89
Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am J Physiol (1993) 0.87
Does periadventitial fat-derived nitric oxide play a role in improved saphenous vein graft patency in patients undergoing coronary artery bypass surgery? J Vasc Res (2007) 0.87
Bisaldehyde allosteric effectors as molecular ratchets and probes. Biochemistry (1995) 0.87
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther (2011) 0.87
Perivascular fat-derived leptin: a potential role in improved vein graft performance in coronary artery bypass surgery. Interact Cardiovasc Thorac Surg (2010) 0.86
Loss of protein kinase Cepsilon results in impaired cutaneous wound closure and myofibroblast function. J Cell Sci (2008) 0.86
Expression and function of heterotypic adhesion molecules during differentiation of human skeletal muscle in culture. Am J Pathol (1992) 0.86
Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) (2006) 0.86
Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood (2001) 0.86
Oral itraconazole therapy for mycotic keratitis. Mycoses (1988) 0.85
Identification of neuronal nitric oxide synthase (nNOS) in human penis: a potential role of reduced neuronally-derived nitric oxide in erectile dysfunction. Curr Pharm Biotechnol (2011) 0.85
Very empirical treatment of solvation and entropy: a force field derived from log Po/w. J Comput Aided Mol Des (2001) 0.85
Design, synthesis, and testing of antisickling agents. 2. Proline derivatives designed for the donor site. J Med Chem (1983) 0.85
Increased angiogenic response but deficient arteriolization and abnormal microvessel ultrastructure in critical leg ischaemia. Br J Surg (2006) 0.85
Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities. J Comput Aided Mol Des (1994) 0.85
Long-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo. J Pharmacol Exp Ther (1982) 0.84
Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol (1998) 0.84
Comparison of crystal and solution hemoglobin binding of selected antigelling agents and allosteric modifiers. Biochemistry (1990) 0.84
X-ray diffraction study of the binding of the antisickling agent 12C79 to human hemoglobin. Proc Natl Acad Sci U S A (1991) 0.83
Vitreous modulation of gene expression in low-passage human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2007) 0.83
Design, synthesis, and testing of potential antisickling agents. 1. Halogenated benzyloxy and phenoxy acids. J Med Chem (1982) 0.83
Low-affinity hemoglobin increases tissue PO2 and decreases arteriolar diameter and flow in the rat cremaster muscle. Microvasc Res (1996) 0.83
Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. Rheumatology (Oxford) (2012) 0.83
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site. J Med Chem (1984) 0.83
Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J Virol (1995) 0.83
KEY, LOCK, and LOCKSMITH: complementary hydropathic map predictions of drug structure from a known receptor-receptor structure from known drugs. J Mol Graph (1992) 0.82
Oral ketoconazole in Keratomycosis. Indian J Ophthalmol (1989) 0.82
Management of degenerative disc disease above an L5-S1 segment requiring arthrodesis. Spine (Phila Pa 1976) (1999) 0.82
Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM (1998) 0.82
Signaling pathways regulating intercellular adhesion molecule 1 expression by endothelin 1: comparison with interleukin-1beta in normal and scleroderma dermal fibroblasts. Arthritis Rheum (2006) 0.82
Hammerhead ribozyme-mediated silencing of the mutant fibrillin-1 of tight skin mouse: insight into the functional role of mutant fibrillin-1. Exp Cell Res (2006) 0.82
Elevated CCN2 expression in scleroderma: a putative role for the TGFβ accessory receptors TGFβRIII and endoglin. J Cell Commun Signal (2011) 0.81
Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol (1998) 0.80
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids. J Med Chem (1984) 0.80
QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction. Proteins (2001) 0.80
Evaluation of the side arm of (naphthylvinyl)pyridinium inhibitors of choline acetyltransferase. J Med Chem (1988) 0.80
Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol (2004) 0.79
A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys (2001) 0.79
Itraconazole therapy for fungal keratitis. Indian J Ophthalmol (1987) 0.79
Reactions of sulfenes with ketene acetals and ketene animals. J Org Chem (1967) 0.79
RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. Am J Physiol (1996) 0.79
Filamentous proteins in Alzheimer's disease: new insights through molecular biology. Psychiatr Dev (1988) 0.79
Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma. Eur J Clin Invest (2009) 0.79
Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis. Rheumatology (Oxford) (2008) 0.78
Nitric oxide manipulation: a therapeutic target for peripheral arterial disease? Cardiol Res Pract (2012) 0.78
HIV- I Nef severely impairs thymocyte development and peripheral T-cell function by a CD4-independent mechanism. Genes Funct (1997) 0.78
Endothelin-1 in peripheral arterial disease: a potential role in muscle damage. Pharmacol Res (2011) 0.78
Effect of distamycin on chlorambucil-induced mutagenesis in pZ189: evidence of a role for minor groove alkylation at adenine N-3. Mutagenesis (1994) 0.78
Structure of tetragonal crystals of human erythrocyte catalase. Acta Crystallogr D Biol Crystallogr (2001) 0.78
Chimeric beta-EF3-alpha hemoglobin (Psi): energetics of subunit interaction and ligand binding. Biochemistry (1998) 0.77